| x | QUARTERLY REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
|---|-----------------------------------------------------------------------------------------|

|  ̈ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
|--------|------------------------------------------------------------------------------------------|

|                                                          |   |                                 |
|---------------------------------------------------------------|--------|--------------------------------------|
| Nevada                                                        |   | 65-0797243                           |
| (State or Other Jurisdiction ofIncorporation or Organization) |   | (I.R.S. Employer Identification No.) |

----

|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | QUICK-MED TECHNOLOGIES, INC. INDEX TO FORM 10-Q                                                                                                                                                                                                                                                                                       |      |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|
| PART I                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | FINANCIAL INFORMATION                                                                                                                                                                                                                                                                                                                           |      |
|  Item 1.             Financial Statements                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                                                                                            |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                                                                                                                                                                                                                                                                                                            |   1  |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Condensed Balance Sheets as of  September 30, 2009   and June 30, 2009 (unaudited)                                       |      |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                                                                                                                                                                                                                                                                                                            |   2  |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Condensed Statements of Operations for the three  months ended September 30, 2009  and2008 (unaudited)                                                                |      |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                                                                                                                                                                                                                                                                                                            |   3  |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Condensed Statement of Changes in Stockholders’ Deficit for the three months ended September30, 2009 (unaudited)                                                                                                                                                                                                                     |      |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                                                                                                                                                                                                                                                                                                            |   4  |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Condensed Statements of Cash Flows for the three months ended September 30, 2009 and 2008 (unaudited)                                                                                                                                                                                                                                           |      |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                                                                                                                                                                                                                                                                                                            |   5  |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Notes to Condensed Financial Statements (unaudited)                                                                                                                                                                                                                                                                                             |      |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                                                                                                                                                                                                                                                                                                            |      |
| Item 2.             Management’s Discussion and Analysis of Financial Conditionand Results of Operations                                                                                       |   13                                                                                                                                                                                                                                                                                                                                       |
| Item 3.              Quantitative and Qualitative Disclosure About Market Risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |   19                                                                                                                                                                                                                                                                                                                                  |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                                                                                                                                                                                                                                                                                                            |      |
| Item 4T.           Controls and Procedures                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                                                                                                                                                                                                                                                                                                                                            |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                                                                                                                                                                                                                                                                                                            |      |
| PART II                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | OTHER INFORMATION                                                                                                                                                                                                                                                                                                                               |      |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                                                                                                                                                                                                                                                                                                            |   20 |
| Item 1.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |  Legal Proceedings                                                                                                                                                                                                                                                                                                                         |      |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                                                                                                                                                                                                                                                                                                            |   20 |
| Item 2.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | Unregistered Sales of Equity Securities and Use of Proceeds                                                                                                                                                                                                                                                                                     |      |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                                                                                                                                                                                                                                                                                                            |   20 |
| Item 3.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | Defaults Upon Senior Securities                                                                                                                                                                                                                                                                                                                 |      |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                                                                                                                                                                                                                                                                                                            |   20 |
| Item 4.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | Submission of Matters to a Vote of Security Holders                                                                                                                                                                                                                                                                                             |      |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                                                                                                                                                                                                                                                                                                            |   20 |
| Item 5.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | Other Information                                                                                                                                                                                                                                                                                                                               |      |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                                                                                                                                                                                                                                                                                                            |   20 |
| Item 6.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | Exhibits                                                                                                                                                                                                                                                                                                                                        |      |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                                                                                                                                                                                                                                                                                                            |   21 |
| SIGNATURES                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                                                                                                                                                                                                                                                                                                            |

|   |   |
|--------|--------|

----

Index

|   |       |
|--------|--------------------------------|
F

C

| ASSETS                                                               |   |          |        |   |     |   |
|----------------------------------------------------------------------|--------|---------------|-------------|--------|----------|--------|
|                                                                 |   | September 30, |        |   | June 30, |   |
|                                                                 |   | 2009          |        |   | 2009     |   |
|                                                                 |   |          |        |   |     |   |
| Current assets:                                                      |   |          |        |   |     |   |
| Cash and cash equivalents                                            |   | $             | 48,217      |   |     | $      | 41,216 |   |
| Accounts receivable                                                  |   |          | 11,751      |   |     |   | 18,562 |   |
| Total current assets                                                 |   |          | 59,968      |   |     |   | 59,778 |   |
|                                                                 |   |          |        |   |     |   |   |   |
| Property and equipment, net                                          |   |          | 12,465      |   |     |   | 14,969 |   |
|                                                                 |   |          |        |   |     |   |   |   |
| Other assets:                                                        |   |          |        |   |     |   |   |   |
| Prepaid expenses                                                     |   |          | 9,624       |   |     |   | 9,706 |   |
| Intangible asset, net                                                |   |          | 400,016     |   |     |   | 408,095 |   |
| Total other assets                                                   |   |          | 409,640     |   |     |   | 417,801 |   |
| Total assets                                                         |   | $             | 482,073     |   |     | $      | 492,548 |   |
|                                                                 |   |          |        |   |     |   |   |   |
| LIABILITIES AND STOCKHOLDERS' DEFICIT                                |   |          |        |   |     |   |   |   |
|                                                                 |   |          |        |   |     |   |   |   |
| Current liabilities:                                                 |   |          |        |   |     |   |   |   |
| Accounts payable                                                     |   | $             | 579,856     |   |     | $      | 562,611 |   |
| Unearned revenue                                                     |   |          | 34,642      |   |     |   | 51,428 |   |
| Accrued expenses                                                     |   |          | 276,151     |   |     |   | 233,631 |   |
| Convertible note payable - related party                             |   |          | 437,877     |   |     |   | 430,315 |   |
| Total current liabilities                                            |   |          | 1,328,526   |   |     |   | 1,277,985 |   |
|                                                                 |   |          |        |   |     |   |   |   |
| License payable                                                      |   |          | 160,000     |   |     |   | 160,000 |   |
| Long-term liability - note payable - officer                         |   |          | 103,994     |   |     |   | 102,482 |   |
| Long-term liability - convertible note payable - director            |   |          | 4,378,515   |   |     |   | 3,916,290 |   |
| Total liabilities                                                    |   |          | 5,971,035   |   |     |   | 5,456,757 |   |
|                                                                 |   |          |        |   |     |   |   |   |
| Commitments and contingencies                                        |   |          |        |   |     |   |   |   |
|                                                                 |   |          |        |   |     |   |   |   |
| Stockholders' deficit:                                               |   |          |        |   |     |   |   |   |
| Common stock, $0.0001 par value; 100,000,000                         |   |          |        |   |     |   |   |   |
| authorized shares; 31,189,613 and 31,039,707 shares issued and       |   |          |        |   |     |
|   outstanding at September and June 30, 2009, respectively |   |          | 3,119       |   |     |   | 3,104 |   |
| Additional paid-in capital                                           |   |          | 12,084,354  |   |     |   | 11,927,286 |   |
| Outstanding stock options                                            |   |          | 3,270,575   |   |     |   | 3,213,987 |   |
| Accumulated deficit                                                  |   |          | (20,847,010 | )      |     |   | (20,108,586 | ) |
| Total stockholders' deficit                                          |   |          | (5,488,962  | )      |     |   | (4,964,209 | ) |
| Total liabilities and stockholders' deficit                          |   | $             | 482,073     |   |     | $      | 492,548 |   |
|                                                                 |   |          |        |   |     |   |   |   |

----

Index

O

|                                               |   | Three Months Ended |       |
|----------------------------------------------------|--------|--------------------|------------|
|                                               |   | September 30,      |       |
|                                               |   | 2009               |       |   | 2008 |   |
|                                               |   |               |       |   |   |   |
| Revenues                                           |   |               |       |   |   |   |
| Product sales                                      |   | $                  | 7,971      |   |   | $ | 711,671 |   |
| Royalty fees                                       |   |               | 4,574      |   |   |   | - |   |
| Research and development service                   |   |               | 15,000     |   |   |   | 19,100 |   |
| License fees                                       |   |               | 1,786      |   |   |   | 1,786 |   |
|                                               |   |               | 29,331     |   |   |   | 732,557 |   |
|                                               |   |               |       |   |   |   |   |   |
| Expenses:                                          |   |               |       |   |   |   |   |   |
| Cost of sales                                      |   |               | 1,159      |   |   |   | 29,922 |   |
| Research and development                           |   |               | 246,691    |   |   |   | 244,929 |   |
| General and administrative expenses                |   |               | 278,490    |   |   |   | 338,249 |   |
| Licensing and patent expenses                      |   |               | 43,814     |   |   |   | 47,773 |   |
| Depreciation and amortization                      |   |               | 17,976     |   |   |   | 17,976 |   |
| Total expenses                                     |   |               | 588,130    |   |   |   | 678,849 |   |
|                                               |   |               |       |   |   |   |   |   |
| Income (loss) from operations                      |   |               | (558,799   | ) |   |   | 53,708 |   |
|                                               |   |               |       |   |   |   |   |   |
| Other income (expense):                            |   |               |       |   |   |   |   |   |
| Interest income                                    |   |               | 7          |   |   |   | 116 |   |
| Interest expense                                   |   |               | (179,632   | ) |   |   | (60,596 | ) |
|                                               |   |               |       |   |   |   |   |   |
| Loss before income taxes                           |   |               | (738,424   | ) |   |   | (6,772 | ) |
|                                               |   |               |       |   |   |   |   |   |
| Provision (benefit) for income taxes               |   |               | -          |   |   |   | - |   |
|                                               |   |               |       |   |   |   |   |   |
| Net loss                                           |   | $                  | (738,424   | ) |   | $ | (6,772 | ) |
|                                               |   |               |       |   |   |   |   |   |
|                                               |   |               |       |   |   |   |   |   |
| Net loss per share (basic and diluted)             |   | $                  | (0.02      | ) |   | $ | - |   |
|                                               |   |               |       |   |   |   |   |   |
| Weighted average common                            |   |               |       |   |   |   |   |   |
|   shares outstanding (basic and diluted) |   |               | 31,186,613 |   |   |   | 30,874,196 |   |
|                                               |   |               |       |   |   |   |   |   |

----

Index

T

|                                           |   |         |      |   |    |   |   |        |   |   |        |   |   |          |        |   |   |   |
|------------------------------------------------|--------|--------------|-----------|--------|---------|--------|--------|-------------|--------|--------|-------------|--------|--------|---------------|-------------|--------|--------|--------|
|                                           |   |         |      |   |    |   |   | Additional  |   |   |        |   |   |          |        |   |   |   |
|                                           |   | Common Stock |      |   | Paid-In |   |   | Accumulated |   |   | Outstanding |   |   |          |        |
|                                           |   | Shares       |      |   | Amount  |   |   | Capital     |   |   | Deficit     |   |   | Stock Options |        |   | Total  |   |
|                                           |   |         |      |   |    |   |   |        |   |   |        |   |   |          |        |   |   |   |
| Balance, June 30, 2009                         |   |         | 3,109,707 |   |    | $      | 3,104  |        |   | $      | 11,927,286  |   |   | $             | (20,108,586 | )      |   | $      | 3,213,987 |   |   | $ | (4,964,209 | ) |
|                                           |   |         |      |   |    |   |   |        |   |   |        |   |   |          |        |   |   |   |   |   |   |   |   |   |
| Stock-based compensation                       |   |         | -         |   |    |   | -      |        |   |   | -           |   |   |          | -           |   |   |   | 82,688 |   |   |   | 82,688 |   |
| Stock issuance for services                    |   |         | 4,906     |   |    |   | -      |        |   |   | 3,000       |   |   |          | -           |   |   |   | - |   |   |   | 3,000 |   |
| Exercise of stock options                      |   |         | 145,000   |   |    |   | 15     |        |   |   | 50,735      |   |   |          | -           |   |   |   | (26,100 | ) |   |   | 24,650 |   |
| Convertible debt beneficial conversion feature |   |         | -         |   |    |   | -      |        |   |   | 103,333     |   |   |          | -           |   |   |   | - |   |   |   | 103,333 |   |
| Net loss, July 1, 2009 to September 30, 2009   |   |         | -         |   |    |   | -      |        |   |   | -           |   |   |          | (738,424    | )      |   |   | - |   |   |   | (738,424 | ) |
|                                           |   |         |      |   |    |   |   |        |   |   |        |   |   |          |        |   |   |   |   |   |   |   |   |   |
| Balance, September 30, 2009                    |   |         | 3,259,613 |   |    | $      | 3,119  |        |   | $      | 12,084,354  |   |   | $             | (20,847,010 | )      |   | $      | 3,270,575 |   |   | $ | (5,488,962 | ) |
|                                           |   |         |      |   |    |   |   |        |   |   |        |   |   |          |        |   |   |   |   |   |   |   |   |   |

----

Index

A

|                                                       |   | 2009   |     |   | 2008   |   |
|------------------------------------------------------------|--------|--------|----------|--------|--------|--------|
| Cash flows from operating activities:                      |   |   |     |   |   |   |
| Net loss                                                   |   | $      | (738,424 | )      |   | $      | (6,772 | ) |
| Adjustments to reconcile net loss to net                   |   |   |     |   |   |   |   |   |
|   cash used in operating activities:             |   |   |     |   |   |   |   |   |
| Depreciation and amortization                              |   |   | 17,976   |   |   |   | 17,976 |   |
| Stock granted for services                                 |   |   | 3,000    |   |   |   | - |   |
| Stock-based compensation                                   |   |   | 82,688   |   |   |   | 113,390 |   |
| Interest expense on convertible debt beneficial conversion |   |   | 103,333  |   |   |   | - |   |
| (Increase) decrease in:                                    |   |   |     |   |   |   |   |   |
| Accounts receivable                                        |   |   | 6,811    |   |   |   | (330,989 | ) |
| Prepaid expenses                                           |   |   | 81       |   |   |   | (4,398 | ) |
| Increase (decrease) in:                                    |   |   |     |   |   |   |   |   |
| Accounts payable                                           |   |   | 17,245   |   |   |   | (183,967 | ) |
| Accrued interest                                           |   |   | 76,299   |   |   |   | 60,596 |   |
| Other current liabilities                                  |   |   | 25,737   |   |   |   | 1,851 |   |
| Net cash used in operating activities                      |   |   | (405,254 | )      |   |   | (332,313 | ) |
|                                                       |   |   |     |   |   |   |   |   |
| Cash flows from investing activities:                      |   |   |     |   |   |   |   |   |
| Patents                                                    |   |   | (7,395   | )      |   |   | (675 | ) |
| Net cash used in investing activities                      |   |   | (7,395   | )      |   |   | (675 | ) |
|                                                       |   |   |     |   |   |   |   |   |
| Cash flows from financing activities:                      |   |   |     |   |   |   |   |   |
| Proceeds from exercise of stock options                    |   |   | 24,650   |   |   |   | - |   |
| Increase in notes payable - director                       |   |   | 395,000  |   |   |   | 300,000 |   |
| Net cash provided by financing activities                  |   |   | 419,650  |   |   |   | 300,000 |   |
|                                                       |   |   |     |   |   |   |   |   |
| Net decrease in cash and cash equivalents                  |   |   | 7,001    |   |   |   | (32,988 | ) |
| Cash and cash equivalents at beginning of period           |   |   | 41,216   |   |   |   | 72,817 |   |
| Cash and cash equivalents at end of period                 |   | $      | 48,217   |   |   | $      | 39,829 |   |
|                                                       |   |   |     |   |   |   |   |   |
| Supplementary Information:                                 |   |   |     |   |   |   |   |   |
|                                                       |   |   |     |   |   |   |   |   |
| Cash paid for:                                             |   |   |     |   |   |   |   |   |
| Interest                                                   |   | $      | -        |   |   | $      | - |   |
| Income taxes                                               |   | $      | -        |   |   | $      | - |   |
|                                                       |   |   |     |   |   |   |   |   |
| Non-cash disclosures of investing and                      |   |   |     |   |   |   |   |   |
|   financing activities:                          |   |   |     |   |   |   |   |   |
| Stock-based compensation                                   |   | $      | 3,000    |   |   | $      | 113,390 |   |
| Interest expense on beneficial conversion                  |   | $      | 103,333  |   |   | $      | - |   |

----

Index

ST

----

Index

----

Index

----

Index

|                    |   |   | 2,009  |   |   |        | 2,008  |   |
|-------------------------|--------|--------|--------|--------|--------|-------------|--------|--------|
| Risk free interest rate |   |   | 3      | %      |   | 4.75% to 6% |   |
| Expected life (years)   |   |   | 5      |   |   |        | 5      |   |
| Expected volatility     |   |   | 161    | %      |   | 50% to 138% |   |
| Expected dividends      |   | None   |   |   | None   |        |

----

Index

|                                    |   | September 30, 2009 |      |   | September 30, 2008 |   |
|-----------------------------------------|--------|--------------------|-----------|--------|--------------------|--------|
|                                    |   | Number             |      |   | Weighted-Average   |   |   | Number |   |   | Weighted-Average |   |
|                                    |   | of Shares          |      |   | Exercise Price     |   |   | of Shares |   |   | Exercise Price |   |
|                                    |   |               |      |   |               |   |   |   |   |   |   |   |
| Outstanding at beginning of period      |   |               | 4,966,116 |   |               | $      | 0.53 |   |   |   | 5,683,544 |   |   | $ | 0.61 |   |
| Granted                                 |   |               | -         |   |               |   | - |   |   |   | - |   |   |   | - |   |
| Exercised                               |   |               | (145,000  | )      |               |   | 0.17 |   |   |   | - |   |   |   | - |   |
| Forfeited                               |   |               | -         |   |               |   | - |   |   |   | (171,647 | ) |   |   | 0.57 |   |
| Expired                                 |   |               | (10,000   | )      |               |   | 0.17 |   |   |   | (871,500 | ) |   |   | 0.55 |   |
| Outstanding at end of period            |   |               | 4,811,116 |   |               | $      | 0.53 |   |   |   | 4,640,397 |   |   | $ | 0.61 |   |
| Exercisable at end of period            |   |               | 3,170,566 |   |               |   |   |   |   |   | 2,839,914 |   |   |   |   |   |
| Available for issuance at end of period |   |               | 764,472   |   |               |   |   |   |   |   | 1,359,603 |   |   |   |   |   |

|                               |   | September 30, 2009 |    |   | September 30, 2008 |   |
|------------------------------------|--------|--------------------|---------|--------|--------------------|--------|
|                               |   | Number             |    |   | Weighted-Average   |   |   | Number |   |   | Weighted-Average |   |
|                               |   | of Shares          |    |   | Exercise Price     |   |   | of Shares |   |   | Exercise Price |   |
|                               |   |               |    |   |               |   |   |   |   |   |   |   |
| Outstanding at beginning of period |   |               | 980,239 |   |               | $      | 0.31 |   |   |   | 744,937 |   |   | $ | 0.48 |   |
| Granted                            |   |               | -       |   |               |   | - |   |   |   | - |   |   |   | - |   |
| Exercised                          |   |               | -       |   |               |   | - |   |   |   | - |   |   |   | - |   |
| Expired                            |   |               | -       |   |               |   | - |   |   |   | - |   |   |   | - |   |
| Outstanding at end of period       |   |               | 980,239 |   |               | $      | 0.31 |   |   |   | 744,937 |   |   | $ | 0.48 |   |
| Exercisable at end of period       |   |               | 812,322 |   |               |   |   |   |   |   | 744,937 |   |   |   |   |   |

|                         |     |   | Interest |   |   | Conversion |   |   | September |     |   | June    |   |
|------------------------------|----------|--------|----------|--------|--------|------------|--------|--------|-----------|----------|--------|---------|--------|
| Related Party                | Maturity |   | Rate     |   |   | Price      |   |   |      | 30, 2009 |   |    |   | 30, 2009 |   |
| 2007 Senior Convertible Note | 2010     |   |     | 8      | %      |       | $      | 0.74   |      |     | $      | 375,000 |   |   | $ | 375,000 |   |
| Accrued interest             |     |   |     |   |   |       |   |   |      |     |   | 62,877  |   |   |   | 55,315 |   |
| Total                        |     |   |     |   |   |       |   |   |      |     | $      | 437,877 |   |   | $ | 430,315 |   |

----

Index

|                                           |     |   | Interest |   |   | Conversion |   |   | September |     |      | June      |   |
|------------------------------------------------|----------|--------|----------|--------|--------|------------|--------|--------|-----------|----------|-----------|-----------|--------|
| Director                                       | Maturity |   | Rate     |   |   | Price      |   |   |      | 30, 2009 |      |      |   | 30, 2009 |   |
| 2003 Senior Convertible Note                   | 2013     |   |     | 6      | %      |       | $      | 0.38   |      |     | $         | 1,268,625 |   |   | $ | 1,268,625 |   |
| Senior Convertible Note                        | 2013     |   |     | 8      | %      |       | $      | 0.74   |      |     |      | 208,955   |   |   |   | 208,955 |   |
| 2007 Senior Convertible Note                   | 2013     |   |     | 8      | %      |       | $      | 0.74   |      |     |      | 375,000   |   |   |   | 375,000 |   |
| 2007 Senior Convertible Note 2                 | 2013     |   |     | 8      | %      |       | $      | 0.55   |      |     |      | 50,000    |   |   |   | 50,000 |   |
| 2007 Senior Convertible Note 2                 | 2013     |   |     | 8      | %      |       | $      | 0.51   |      |     |      | 50,000    |   |   |   | 50,000 |   |
| 2007 Senior Convertible Note 2                 | 2013     |   |     | 8      | %      |       | $      | 0.40   |      |     |      | 50,000    |   |   |   | 50,000 |   |
| 2007 Senior Convertible Note 2                 | 2013     |   |     | 8      | %      |       | $      | 0.40   |      |     |      | 50,000    |   |   |   | 50,000 |   |
| 2007 Senior Convertible Note 2                 | 2013     |   |     | 8      | %      |       | $      | 0.34   |      |     |      | 50,000    |   |   |   | 50,000 |   |
| 2007 Senior Convertible Note 2                 | 2013     |   |     | 8      | %      |       | $      | 0.32   |      |     |      | 50,000    |   |   |   | 50,000 |   |
| 2008 Senior Convertible Note 1                 | 2013     |   |     | 8      | %      |       | $      | 0.32   |      |     |      | 50,000    |   |   |   | 50,000 |   |
| 2008 Senior Convertible Note 1                 | 2013     |   |     | 8      | %      |       | $      | 0.45   |      |     |      | 70,000    |   |   |   | 70,000 |   |
| 2008 Senior Convertible Note 1                 | 2013     |   |     | 8      | %      |       | $      | 0.40   |      |     |      | 75,000    |   |   |   | 75,000 |   |
| 2008 Senior Convertible Note 1                 | 2013     |   |     | 8      | %      |       | $      | 0.33   |      |     |      | 50,000    |   |   |   | 50,000 |   |
| 2008 Senior Convertible Note 1                 | 2013     |   |     | 8      | %      |       | $      | 0.42   |      |     |      | 75,000    |   |   |   | 75,000 |   |
| 2008 Senior Convertible Note 1                 | 2013     |   |     | 8      | %      |       | $      | 0.40   |      |     |      | 50,000    |   |   |   | 50,000 |   |
| 2008 Senior Convertible Note 2                 | 2013     |   |     | 8      | %      |       | $      | 0.29   |      |     |      | 50,000    |   |   |   | 50,000 |   |
| 2008 Senior Convertible Note 2                 | 2013     |   |     | 8      | %      |       | $      | 0.20   |      |     |      | 50,000    |   |   |   | 50,000 |   |
| 2008 Senior Convertible Note 2                 | 2013     |   |     | 8      | %      |       | $      | 0.38   |      |     |      | 50,000    |   |   |   | 50,000 |   |
| 2008 Senior Convertible Note 2                 | 2013     |   |     | 8      | %      |       | $      | 0.35   |      |     |      | 135,000   |   |   |   | 135,000 |   |
| 2008 Senior Convertible Note 2                 | 2013     |   |     | 8      | %      |       | $      | 0.25   |      |     |      | 100,000   |   |   |   | 100,000 |   |
| 2008 Senior Convertible Note 2                 | 2013     |   |     | 8      | %      |       | $      | 0.35   |      |     |      | 50,000    |   |   |   | 50,000 |   |
| 2008 Senior Convertible Note 2                 | 2013     |   |     | 8      | %      |       | $      | 0.25   |      |     |      | 50,000    |   |   |   | 50,000 |   |
| 2008 Senior Convertible Note 3                 | 2013     |   |     | 8      | %      |       | $      | 0.36   |      |     |      | 50,000    |   |   |   | 50,000 |   |
| 2008 Senior Convertible Note 3                 | 2013     |   |     | 8      | %      |       | $      | 0.19   |      |     |      | 50,000    |   |   |   | 50,000 |   |
| 2008 Senior Convertible Note 3                 | 2013     |   |     | 8      | %      |       | $      | 0.31   |      |     |      | 50,000    |   |   |   | 50,000 |   |
| 2009 Senior Convertible Note 1                 | 2013     |   |     | 8      | %      |       | $      | 0.18   |      |     |      | 35,000    |   |   |   | 35,000 |   |
| 2009 Senior Convertible Note 1                 | 2013     |   |     | 8      | %      |       | $      | 0.37   |      |     |      | 35,000    |   |   |   | 35,000 |   |
| 2009 Senior Convertible Note 1                 | 2013     |   |     | 8      | %      |       | $      | 0.43   |      |     |      | 35,000    |   |   |   | 35,000 |   |
| 2009 Senior Convertible Note 1                 | 2013     |   |     | 8      | %      |       | $      | 0.43   |      |     |      | 35,000    |   |   |   | 35,000 |   |
| 2009 Senior Convertible Note 1                 | 2013     |   |     | 8      | %      |       | $      | 0.45   |      |     |      | 35,000    |   |   |   | 35,000 |   |
| 2009 Senior Convertible Note 2                 | 2013     |   |     | 8      | %      |       | $      | 0.48   |      |     |      | 35,000    |   |   |   | 35,000 |   |
| 2009 Senior Convertible Note 2                 | 2013     |   |     | 8      | %      |       | $      | 0.47   |      |     |      | 35,000    |   |   |   | 35,000 |   |
| 2009 Senior Convertible Note 2                 | 2013     |   |     | 8      | %      |       | $      | 0.42   |      |     |      | 35,000    |   |   |   | 35,000 |   |
| 2009 Senior Convertible Note 2                 | 2013     |   |     | 8      | %      |       | $      | 0.53   |      |     |      | 35,000    |   |   |   | 35,000 |   |
| 2009 Senior Convertible Note 2                 | 2013     |   |     | 8      | %      |       | $      | 0.58   |      |     |      | 35,000    |   |   |   | 35,000 |   |
| 2009 Senior Convertible Note 2                 | 2013     |   |     | 8      | %      |       | $      | 0.52   |      |     |      | 35,000    |   |   |   | - |   |
| 2009 Senior Convertible Note 2                 | 2013     |   |     | 8      | %      |       | $      | 0.46   |      |     |      | 35,000    |   |   |   | - |   |
| 2009 Senior Convertible Note 2                 | 2013     |   |     | 8      | %      |       | $      | 0.55   |      |     |      | 35,000    |   |   |   | - |   |
| 2009 Senior Convertible Note 2                 | 2013     |   |     | 8      | %      |       | $      | 0.63   |      |     |      | 50,000    |   |   |   | - |   |
| 2009 Senior Convertible Note 2                 | 2013     |   |     | 8      | %      |       | $      | 0.60   |      |     |      | 45,000    |   |   |   | - |   |
| 2009 Senior Convertible Note 3                 | 2013     |   |     | 8      | %      |       | $      | 0.60   |      |     |      | 45,000    |   |   |   | - |   |
| 2009 Senior Convertible Note 3                 | 2013     |   |     | 8      | %      |       | $      | 0.60   |      |     |      | 25,000    |   |   |   | - |   |
| 2009 Senior Convertible Note 3                 | 2013     |   |     | 8      | %      |       | $      | 0.60   |      |     |      | 125,000   |   |   |   | - |   |
| Accrued interest                               |     |   |     |   |   |       |   |   |      |     |      | 475,935   |   |   |   | 408,710 |   |
|                                           |     |   |     |   |   |       |   |   |      |     |      | 4,378,515 |   |   |   | 3,916,290 |   |
| Officer                                        |     |   |     |   |   |       |   |   |      |     |      |      |   |   |   |   |   |
| 2008 Convertible Notes                         | 2010     |   |     | 8      | %      |       | $      | 0.20   |      |     |      | 100,000   |   |   |   | 100,000 |   |
| Accrued interest                               |     |   |     |   |   |       |   |   |      |     |      | 3,994     |   |   |   | 2,482 |   |
|                                           |     |   |     |   |   |       |   |   |      |     |      | 103,994   |   |   |   | 102,482 |   |
|                                           |     |   |     |   |   |       |   |   |      |     |      |      |   |   |   |   |   |
|    Total long term note payable |     |   |     |   |   |       |   |   |      |     | 4,482,509 |      |   |   | 4,018,772 |   |
|                                           |     |   |     |   |   |       |   |   |      |     |      |      |   |   |   |   |   |
| Total debt                                     |     |   |     |   |   |       |   |   |      |     | $         | 4,920,386 |   |   | $ | 4,449,087 |   |

----

Index

----

Index

|                                                            |   | Carrying Value |      |   | Level 1 |   |   | Level 2 |   |   | Level 3 |   |
|-----------------------------------------------------------------|--------|----------------|-----------|--------|---------|--------|--------|---------|--------|--------|---------|--------|
| Financial Assets                                                |   |           |      |   |    |   |   |    |   |   |    |   |
|    Cash equivalents (1)                          |   | $              | 32,198    |   |    | $      | 32,198 |    |   |   | -       |   |   |   | - |   |
|       Total financial assets      |   | $              | 32,198    |   |    | $      | 32,198 |    |   |   | -       |   |   |   | - |   |
|                                                            |   |           |      |   |    |   |   |    |   |   |    |   |   |   |   |   |
|                                                            |   |           |      |   |    |   |   |    |   |   |    |   |   |   |   |   |
|                                                            |   | Carrying Value |      |   | Level 1 |   |   | Level 2 |   |   | Level 3 |   |
| Financial Liabilities                                           |   |           |      |   |    |   |   |    |   |   |    |   |   |   |   |   |
|    Convertible notes payable (2)                 |   | $              | 4,896,514 |   |    |   | -      |    |   |   | -       |   |   | $ | 4,896,514 |   |
|       Total financial liabilities |   | $              | 4,896,514 |   |    |   | -      |    |   |   | -       |   |   | $ | 4,896,514 |   |

----

Index

| ITEM 2. | MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS |
|---------|---------------------------------------------------------------------------------------|

|   | · | License fees; |
|--------|--------|---------------|

|   | · | Profit sharing revenues; |
|--------|--------|--------------------------|

|   | · | Research and development fees paid to us in connection with joint development agreements; and |
|--------|--------|-----------------------------------------------------------------------------------------------|

|   | · | Government research and development grants. |
|--------|--------|---------------------------------------------|

| ·   | Healthcare and medical; |
|--------------------|-------------------------|

| ·   | Apparel and textile; and |
|--------------------|--------------------------|

| ·   | Personal care companies. |
|--------------------|--------------------------|

----

Index

|   | · | Acceptance of our products or future products in the marketplace; |
|--------|--------|-------------------------------------------------------------------|

|   | · | Our partners’ ability to develop, market and distribute our technologies under a strategic   partnership agreement; |
|--------|--------|------------------------------------------------------------------------------------------------------------------------------------------|

|   | · | Demand for products or future products that utilize our technologies; |
|--------|--------|-----------------------------------------------------------------------|

|   | · | Our ability to secure license or profit sharing related agreements and secure government research and development grants; |
|--------|--------|---------------------------------------------------------------------------------------------------------------------------|

|   | · | Our ability to market our services to health care, apparel, cosmetic, and personal care companies; |
|--------|--------|----------------------------------------------------------------------------------------------------|

|   | · | Our ability to successfully conduct laboratory and clinical testing of our potential products; and |
|--------|--------|----------------------------------------------------------------------------------------------------|

|   | · | Our ability to obtain regulatory approval of our future products. |
|--------|--------|-------------------------------------------------------------------|

----

Index

----

Index

| ·   | Voluntary deferral of $100,000 or 40% of our Chief Executive Officer’s annual salary; |
|--------------------|---------------------------------------------------------------------------------------------|

| ·   | Voluntary deferral of totaling $71,250 or 25% of our Vice President of Research and Development and Chief Financial Officer’s annual salary or consulting fee; |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| ·   | Reduction of a $75,000 salary position; and |
|--------------------|---------------------------------------------|

| ·   | Deferral of $20,000 or 20% in patent consulting fee. |
|--------------------|------------------------------------------------------|

| ·   | Additional voluntary deferral of $25,000 or $125,000 in total or 50% of our Chief Executive Officer’s annual salary; |
|--------------------|----------------------------------------------------------------------------------------------------------------------------|

| ·   | Additional voluntary deferral of totaling $71,250 or $142,500 in total or 50% of our Vice President of Research and Development and Chief Financial Officer’s annual salary or consulting fee; |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| ·   | Voluntary deferral of totaling $10,000 or 8% of our Director of Business Development.  Effective October 1, 2009, the salary of our Director of Business Development was fully restored. |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

Index

|   | · | Research and development expenditures of approximately $74,000 per month or an aggregate $888,000 over the next twelve (12) months, which will consist of the following estimated monthly expenditures: (a) $50,000 in payroll for scientists; (b) $7,000 for outside research and development expenditures; and (c) $17,000 for chemical supplies and laboratory operating expenses, including rent expense; |
|--------|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | · | Patent related legal fees of approximately $18,334 per month or an aggregate $220,000 annually; and |
|--------|--------|-----------------------------------------------------------------------------------------------------|

|   | · | Operating expenses of approximately $50,667 per month or an aggregate $608,000 over the next twelve (12) months, including personnel costs, director and officer insurance, general liability insurance, rent, consulting fees, utilities, legal and accounting fees, and payroll. |
|--------|--------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

Index

| ·   | Significantly reduce, eliminate or curtail our business, operating and research and development activities so as to reduce operating costs; |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------|

| ·   | Sell, assign or otherwise dispose of our assets, if any, to raise cash or to settle claims by creditors, including our Chairman of the Board; |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------|

| ·   | Pay our liabilities in order of priority, if we have available cash to pay such liabilities; |
|--------------------|----------------------------------------------------------------------------------------------|

| ·   | If any cash remains after we satisfy amounts due to our creditors, distribute any remaining cash to our shareholders in an amount equal to the net market value of our net assets; |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| ·   | File a Certificate of Dissolution with the State of Nevada to dissolve our corporation and close our business; |
|--------------------|----------------------------------------------------------------------------------------------------------------|

| ·   | Make the appropriate filings with the Securities and Exchange Commission so that we will no longer be required to file periodic and other required reports with the Securities and Exchange Commission, if, in fact, we are a reporting company at that time; and |
|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| ·   | Make the appropriate filings with the National Association of Security Dealers to affect a delisting of our stock. |
|--------------------|--------------------------------------------------------------------------------------------------------------------|

|                            |   | Total |      |   | Less than 1 Year |   |    | 1-3 Years |   |   | 3-5 Years |   |   | More than 5 Years |      |
|---------------------------------|--------|-------|-----------|--------|------------------|--------|---------|-----------|--------|--------|-----------|--------|--------|-------------------|-----------|
| Long-term debt obligations (a)  |   | $     | 4,920,386 |   |             | $      | 437,877 |      |   | $      | 103,994   |   |   | $                 | 4,378,515 |   |   | $ | - |   |
| Operating lease obligations (b) |   | $     | 32,000    |   |             | $      | 24,000  |      |   | $      | 8,000     |   |   | $                 | -         |   |   | $ | - |   |

| (a)   | The principal and accrued interest on the notes payable owed to the Chairman’s Senior Convertible Notes, to an officer’s convertible note payable, and to a major shareholder’s senior note payable as fully discussed in note 4 of the accompanying condensed footnotes to the   financial statements. |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (b)   | We have an operating lease for our laboratory in Gainesville, Florida with an expiration date in 2011. |
|-----------------|--------------------------------------------------------------------------------------------------------|

----

Index

3

.

o

----

Index

l 

 2

s

n

O

Ex

| Exhibit Number |   | Description                                                                                                                                                            |
|----------------|--------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|           |   |                                                                                                                                                                   |
| 2.1            |   | Merger Agreement dated March 19, 2001 between Above Average Investments Ltd. and Quick-Med Technologies, Inc. (1)                                                      |
|           |   |                                                                                                                                                                   |
| 2.2            |   | Amendment to Merger Agreement (1)                                                                                                                                      |
|           |   |                                                                                                                                                                   |
| 3.1            |   | Articles of Incorporation (1)                                                                                                                                          |
|           |   |                                                                                                                                                                   |
| 3.2            |   | Bylaws (1)                                                                                                                                                             |
|           |   |                                                                                                                                                                   |
| 10.1           |   | 2009 Senior Convertible Note 3 issued to Michael Granito filed herewith.                                                                                               |
|           |   |                                                                                                                                                                   |
| 10.2           |   | Joint Development and Exclusive Option Agreement by and between Avery Dennison and the Registrant dated as of April 17, 2009(2)                                        |
|           |   |                                                                                                                                                                   |
| 31.1           |   | Certification of Principal Executive Officer Pursuant to Rule 13a-14(a) and 15d-14(a), filed herewith.                                                                 |
|           |   |                                                                                                                                                                   |
| 31.2           |   | Certification of Chief Financial Officer Pursuant to Rule 13a-14(a) and 15d-14(a), filed herewith.                                                                     |
|           |   |                                                                                                                                                                   |
| 32.1           |   | Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, filed herewith. |
|           |   |                                                                                                                                                                   |
| 32.2           |   | Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, filed herewith.     |
|           |   |                                                                                                                                                                   |

----

Index

S

|   | Quick-Med Technologies, Inc. |
|--------|------------------------------|
|   | ___________________________  |
|   | (Registrant)                 |

|   |              |                                                  |
|--------|-------------------|-------------------------------------------------------|
| Date   | November 16, 2009 | By: /s/ J. Ladd Greeno                                |
|   |              | J. Ladd Greeno                                        |
|   |              | Chief Executive Officer (Principal Executive Officer) |

| Date   | November 16, 2009 | By: /s/ Nam H. Nguyen   |
|--------|-------------------|-------------------------|
|   |              | Nam H. Nguyen           |
|   |              | Chief Financial Officer |

----